Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 26059 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Trading Down 50.0 %
The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The stock has a market capitalization of C$663,150.00, a price-to-earnings ratio of -0.50 and a beta of -0.02. The firm has a 50-day moving average of C$0.01 and a 200 day moving average of C$0.01.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
See Also
- Five stocks we like better than Aequus Pharmaceuticals
- What is MarketRank™? How to Use it
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- 3 REITs to Buy and Hold for the Long Term
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- How to Invest in the FAANG Stocks
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
